Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

SAREPTA THERAPEUTICS INC

(SRPT)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2019 06/20/2019 06/21/2019 06/24/2019 06/25/2019 Date
134.41(c) 130.19(c) 129.88(c) 127.34(c) 124.16 Last
1 770 062 1 000 255 1 050 807 852 579 1 010 901 Volume
+1.58% -3.14% -0.24% -1.96% -2.50% Change
More quotes
Financials (USD)
Sales 2019 389 M
EBIT 2019 -336 M
Net income 2019 -309 M
Finance 2019 724 M
Yield 2019 -
Sales 2020 608 M
EBIT 2020 -203 M
Net income 2020 -184 M
Finance 2020 730 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 22,4x
EV / Sales2020 14,3x
Capitalization 9 443 M
More Financials
Company
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to... 
More about the company
Surperformance© ratings of Sarepta Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on SAREPTA THERAPEUTICS INC
06/07SAREPTA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders..
AQ
06/04Sarepta Therapeutics to Present at the Goldman Sachs 40th Annual Global Healt..
GL
05/31Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 56..
GL
05/23SAREPTA THERAPEUTICS : Statement on ICER Draft Evidence Report for Treatments fo..
PU
05/23CATALENT : new prize, Paragon, adding capacity to make Sarepta gene therapies
AQ
05/09SAREPTA THERAPEUTICS : Announces Agreement with Nationwide Children's Hospital f..
AQ
05/09SAREPTA THERAPEUTICS : Announces Agreement with Nationwide Childrens Hospital fo..
AQ
05/08SAREPTA THERAPEUTICS : 1Q Earnings Snapshot
AQ
05/08SAREPTA THERAPEUTICS : Announces First Quarter 2019 Financial Results and Recent..
AQ
05/08SAREPTA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
AQ
More news
Analyst Recommendations on SAREPTA THERAPEUTICS INC
More recommendations
Sector news : Bio Therapeutic Drugs
06/21Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results
DJ
06/20EXELIXIS : Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint
DJ
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/19GILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
More sector news : Bio Therapeutic Drugs
Chart SAREPTA THERAPEUTICS INC
Duration : Period :
Sarepta Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAREPTA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 204 $
Spread / Average Target 60%
EPS Revisions
Managers
NameTitle
Douglas S. Ingram President, Chief Executive Officer & Director
M. Kathleen Behrens Chairman
Sandesh Mahatme Executive VP, Chief Financial & Business Officer
Guriqbal S. Basi Chief Scientific Officer
Gilmore O’Neill Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS INC16.69%8 523
GILEAD SCIENCES10.06%80 909
VERTEX PHARMACEUTICALS9.24%42 680
REGENERON PHARMACEUTICALS-16.32%32 744
GENMAB12.51%10 857
NEUROCRINE BIOSCIENCES, INC.18.33%7 500